Interview: Chris Garabedian
Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.
May 2016: Therapeutic Innovation & Regulatory Science: Focus on Pharmaceutical Compounding
FDA's Accelerated Pathways Are the New Normal (And They Work If You Work Them)
It's a Revolution: Real World Data and Health Outcomes
Building Regulatory Capacity: MRCT Workshop in Singapore
Disease Interception and the US National Cancer Moonshot
"A Gathering of Global Proportions" at DIA 2016